1. Home
  2. FOLD vs ADMA Comparison

FOLD vs ADMA Comparison

Compare FOLD & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amicus Therapeutics Inc.

FOLD

Amicus Therapeutics Inc.

HOLD

Current Price

$14.36

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Logo ADMA Biologics Inc

ADMA

ADMA Biologics Inc

HOLD

Current Price

$16.81

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOLD
ADMA
Founded
2002
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.6B
IPO Year
2006
2012

Fundamental Metrics

Financial Performance
Metric
FOLD
ADMA
Price
$14.36
$16.81
Analyst Decision
Buy
Strong Buy
Analyst Count
9
2
Target Price
$27.25
$28.50
AVG Volume (30 Days)
4.2M
2.5M
Earning Date
01-01-0001
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
50.00
N/A
EPS
N/A
0.60
Revenue
N/A
$42,219,783.00
Revenue This Year
$20.55
$26.71
Revenue Next Year
$18.34
$21.78
P/E Ratio
N/A
$27.84
Revenue Growth
N/A
43.85
52 Week Low
$5.66
$13.76
52 Week High
$14.38
$25.67

Technical Indicators

Market Signals
Indicator
FOLD
ADMA
Relative Strength Index (RSI) 73.35 53.49
Support Level $14.21 $16.39
Resistance Level $14.37 $17.90
Average True Range (ATR) 0.04 0.82
MACD -0.04 0.07
Stochastic Oscillator 93.75 85.25

Price Performance

Historical Comparison
FOLD
ADMA

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Share on Social Networks: